SLC5A2 and acute coronary syndrome: Heart failure was lower among patients on SGLT-2 inhibitors compared to metformin (P-value, 0.01, chai-square, 14.59, and I2 for heterogeneity, 86%, P-value for heterogeneity <0.001) and the acute coronary syndrome was lower among patients initiated SGLT-2 inhibitors as the first line (P-value, 0.01, chai-square, 9.59, and I2 for heterogeneity, 79%, P-value for heterogeneity <0.001), Fig.3 and 4.